Visit the Biotech CEO Summit 2015

Questions that Cause Biotech CEOs to Lose Sleep: Should I divert funds to the new and promising program or stay focused? Does my team have the skills to take us to the next level? Is our board the right board for the company we want to be? How can I get the best...

Cortendo adds two late‐stage assets and announces $33M financing

Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing Cortendo Enters Into Agreements to Acquire Aspireo Pharmaceuticals’ Somatoprim (DG3173) and In-License Antisense Therapeutics’ ATL1103...